A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors.

ABSTRACT:

Background

This window of opportunity trial evaluated the safety of intratumoral Copaxone® and profiled immune markers in biopsies before and after treatment.

Methods

Patients with percutaneously accessible malignancies scheduled for surgical resection with curative intent were eligible to participate. Adverse events from one, two, or three injections of Copaxone® were monitored leading up to surgical resection. Using RNA sequencing and spatial protein profiling of immune-related targets, changes in mRNA and protein expression patterns, respectively were assessed in tumor biopsy samples pre- and post-treatment.

Results

Adverse events at the injection site were mild and consistent with historic subcutaneous administration of Copaxone®. Increased intratumoral immune act

SUBMITTER: Baranda JC 

PROVIDER: S-EPMC11996204 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature